December 17, 2025 USA
Two leading voices in the evolving landscape of type 1 diabetes research, Dr. Joshua Vieth, Senior Director of Research at Breakthrough T1D, and Becky Sulik, Director of Education at the Rocky Mountain Diabetes Center, feature in a new article examining how biomarkers are driving progress toward disease-modifying therapies that go beyond insulin replacement. The piece highlights the importance of C-peptide as a surrogate endpoint and showcases collaborations with companies such as Diamyd Medical to accelerate precision immunotherapies. Read the article here
|
December 15, 2025 Sweden
During December 7–13, a U.S. life science delegation participated in Venture Road Nordics, an initiative organized by Ventures Accelerated and Phosworks to strengthen collaboration between the U.S. and the Nordic region. The program included visits to Stockholm and Uppsala, where Diamyd Medical was highlighted. Read the article here
|
December 2, 2025 Sweden
Den 27 november samlades ledande aktörer i life science-branschen för att diskutera hur hållbarhetsarbete och innovation kan stärka både konkurrenskraft och samhällsresiliens. Lif lyfte fram hur medlemsföretagen lever upp till åtagandena i hållbarhetsmanifestet – inklusive färdplanen för fossilfri konkurrenskraft. I anslutning till konferensen presenterades flera konkreta exempel på hållbar produktion, bland dem Diamyd Medicals anläggning i Umeå, som med hjälp av Cytivas single-use-teknik minskar både vatten- och energiförbrukning. Läs artikeln härSe konferensen här
|
November 28, 2025 Sweden
Bolagspresentation av vd Ulf Hannelius från Stora Aktiedagarna i Stockholm den 27 november 2025. Aktiedagarna arrangeras av Aktiespararna.
|
November 19, 2025 USA
On October 25-27 2025 Breakthrough T1D gathered leading experts from academia, biotech and pharma to discuss how disease-modifying therapies can change the course of type 1 diabetes from the earliest stages. This recording from one of the panel session highlighted progress from Stage 2 treatments like teplizumab toward new applications in Stage 3, as well as next-generation immunotherapies from Sanofi, Eli Lilly and Diamyd Medical targeting different immune pathways and specific genetic subgroups. A central theme was the need to treat T1D as an autoimmune disease, not only a glucose/insulin problem, and to secure regulatory acceptance of C-peptide as a key endpoint, while also addressing two urgent challenges: scaling up screening for at-risk individuals in stages 1–2, and speeding clinical trial recruitment and regulatory pathways so that effective therapies reach patients earlier and more widely.
Panel participants: Michael Haller, Professor of Pediatrics, University of Florida; Michelle Katz, Pediatric Endocrinologist, Eli Lilly; Monica Kumar, Senior Global Project Head, Sanofi; Anton Lindqvist, Chief Scientific Officer, Diamyd Medical. Moderated by Sanjoy Dutta, Ph.D., Breakthrough T1D’s Chief Scientific Officer.
|